Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 28:2022:4604601.
doi: 10.1155/2022/4604601. eCollection 2022.

Comparative Pharmacokinetics of Seven Major Compounds in Normal and Atherosclerosis Mice after Oral Administration of Simiao Yong'an Decoction

Affiliations

Comparative Pharmacokinetics of Seven Major Compounds in Normal and Atherosclerosis Mice after Oral Administration of Simiao Yong'an Decoction

Ke-Han Sun et al. Evid Based Complement Alternat Med. .

Abstract

Simiao Yong'an decoction (SMYAD), a classic traditional Chinese medicine formula, has been used to treat atherosclerosis (AS) in clinical in China, but its therapeutic mechanism and pharmacodynamic material basis are not clear. In this study, the AS model was caused by a high-fat diet and perivascular carotid collar placement (PCCP), and SMYAD was orally administered to the model and normal mice. A rapid, sensitive, selective, and reliable method using ultrahigh-performance liquid chromatography (UHPLC) system combined with a Q Exactive HF-X mass spectrometer (UHPLC-Q Exactive HF-X MS) was established and validated for the simultaneous determination of seven compounds, including harpagide, chlorogenic acid, swertiamarin, sweroside, angoroside C, liquiritin, and isoliquiritigenin in the plasma of normal and AS mice. The specificity, linearity, precision, accuracy, recovery, and stability of the method were all within the acceptable criteria. The results showed that some pharmacokinetic behaviors of harpagide, chlorogenic acid, and isoliquiritigenin were significantly different among the two groups of mice. The specific parameter changes were harpagide (AUC0-t and AUC0-∞ were 11075.09 ± 2132.38 and 16221.95 ± 5622.42 ng·mL-1·h, respectively; CLz/F was 2.45 ± 0.87 L/h/mg), chlorogenic acid (t 1/2 was 21.59 ± 9.16 h; AUC0-∞ was 2637.51 ± 322.54 ng·mL-1·h; CLz/F was 13.49 ± 1.81 L/h/mg) and isoliquiritigenin (AUC0-t and AUC0-∞ were 502.25 ± 165.65 and 653.68 ± 251.34 ng·mL-1·h, respectively; CLz/F was 62.16 ± 23.35 L/h/mg) were altered under the pathological status of AS. These differences might be partly ascribed to the changes in gastrointestinal microbiota, nonspecific drug transporters, and cytochrome P450 activity under the AS state, providing research ideas and experimental basis for pharmacological effects and pharmacodynamic material basis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structures and mass spectrum of the seven compounds and IS.
Figure 2
Figure 2
HE-stained carotid artery sections from NC and AS model. (a) NC group; (b) AS group (magnification, ×20).
Figure 3
Figure 3
Extracted-ion chromatograms of harpagide, chlorogenic acid, swertiamarin, sweroside, angoroside C liquiritin, isoliquiritigenin, and IS. (a) Blank plasma; (b) blank plasma spiked with the seven target analytes and IS; (c) drug-containing plasma after administration of SMYAD.
Figure 4
Figure 4
Mean concentration-time curves of seven compounds in NC and ASmouse plasma after oral administration of SMYAD (mean ± SD, n = 5). (a) Harpagide; (b) chlorogenic acid; (c) swertiamarin; (d) sweroside; (e) angoroside C; (f) liquiritin; (g) isoliquiritigenin.

Similar articles

Cited by

References

    1. Falk E. Pathogenesis of atherosclerosis. Journal of the American College of Cardiology . 2006;47(8):C7–C12. doi: 10.1016/j.jacc.2005.09.068. - DOI - PubMed
    1. Gao Z., Xu X., Li Y., et al. Mechanistic insight into PPARγ and tregs in atherosclerotic immune inflammation. Frontiers in Pharmacology . 2021;12 doi: 10.3389/fphar.2021.750078.750078 - DOI - PMC - PubMed
    1. Arnett D. K., Blumenthal R. S., Albert M. A., et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Journal of the American College of Cardiology . 2019;74(10):1376–1414. doi: 10.1016/j.jacc.2019.03.009. - DOI - PMC - PubMed
    1. Collins R., Reith C., Emberson J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet . 2016;388(10059):2532–2561. doi: 10.1016/S0140-6736(16)31357-5. - DOI - PubMed
    1. Li T.-T., Wang Z.-B., Li Y., Cao F., Yang B.-Y., Kuang H.-X. The mechanisms of traditional Chinese medicine underlying the prevention and treatment of atherosclerosis. Chinese Journal of Natural Medicines . 2019;17(6):401–412. doi: 10.1016/s1875-5364(19)30048-2. - DOI - PubMed